These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1579 related articles for article (PubMed ID: 20039405)
1. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M; Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405 [TBL] [Abstract][Full Text] [Related]
2. Modern treatment strategies in rheumatoid arthritis. Hetland ML Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935 [TBL] [Abstract][Full Text] [Related]
3. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150 [TBL] [Abstract][Full Text] [Related]
4. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315 [TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040 [TBL] [Abstract][Full Text] [Related]
6. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G; J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933 [TBL] [Abstract][Full Text] [Related]
7. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Gniadecki R; Kragballe K; Dam TN; Skov L Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290 [TBL] [Abstract][Full Text] [Related]
8. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR; Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821 [TBL] [Abstract][Full Text] [Related]
10. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182 [TBL] [Abstract][Full Text] [Related]
12. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Symmons DP; Watson KD; Silman AJ; Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520 [TBL] [Abstract][Full Text] [Related]
14. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Carter CT; Changolkar AK; Scott McKenzie R J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788 [TBL] [Abstract][Full Text] [Related]
15. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Greenberg JD; Reed G; Decktor D; Harrold L; Furst D; Gibofsky A; Dehoratius R; Kishimoto M; Kremer JM; Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625 [TBL] [Abstract][Full Text] [Related]
16. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231 [TBL] [Abstract][Full Text] [Related]
17. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
18. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849 [TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. Bonafede MM; Gandra SR; Fox KM; Wilson KL J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705 [TBL] [Abstract][Full Text] [Related]
20. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Kristensen LE; Saxne T; Geborek P Arthritis Rheum; 2006 Feb; 54(2):600-6. PubMed ID: 16447237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]